MicroRNA‑623 inhibits tumor progression and is a predictor of poor prognosis of breast cancer

Wang,Chunfeng; Wang,Juan; Zhang,Jing; Li,Yongxiang; Sun,Qinghui; Guo,Feng; An,Xiupeng

doi:10.3892/ol.2020.12249

MicroRNA‑623 inhibits tumor progression and is a predictor of poor prognosis of breast cancer

Authors:
- Chunfeng Wang
- Juan Wang
- Jing Zhang
- Yongxiang Li
- Qinghui Sun
- Feng Guo
- Xiupeng An
View Affiliations

Affiliations: Department of Thyroid and Breast Surgery, The Second People's Hospital of Liaocheng, The Second Hospital of Liaocheng Affiliated to Shandong First Medical University, Linqing of Liaocheng, Shandong 252600, P.R. China, Department of Hematology and Oncology, The People's Hospital of Linqing, Linqing of Liaocheng, Shandong 252600, P.R. China, Department of Emergency, The Second People's Hospital of Liaocheng, The Second Hospital of Liaocheng Affiliated to Shandong First Medical University, Linqing of Liaocheng, Shandong 252600, P.R. China
Published online on: October 29, 2020 https://doi.org/10.3892/ol.2020.12249
Article Number: 386
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dysregulated microRNAs (miRNAs) serve vital roles in the progression and prognosis of breast cancer. miR‑623 has been reported to influence the progression of numerous other cancers, such as lung adenocarcinoma and hepatocellular carcinoma, however, its role in breast cancer remains unclear. In the present study, the mRNA expression of miR‑623 was studied in 121 pairs of breast cancer and adjacent normal tissues and cultured cell lines by reverse‑transcription quantitative PCR. The association between miR‑623 expression and clinical characteristics or the overall survival rate of patients was investigated by the χ2 test or Cox regression analysis, respectively. The role of miR‑623 in cell proliferation, migration and invasion of breast cancer cells was evaluated by cell transfection to regulate miR‑623 expression and the CCK8 and Transwell assays, respectively. miR‑623 was downregulated in breast cancer tissues and cell lines compared with normal tissues and breast epithelial cell lines. The χ2 test demonstrated that the downregulation of miR‑623 was associated with the tumor node metastasis (TNM) stage of patients with breast cancer. miR‑623 and TNM stage were considered as two independent prognostic factors for breast cancer. Additionally, cell proliferation, migration, and invasion of breast cancer cells were promoted by the downregulation of miR‑623, while upregulation of miR‑623 led to inhibition of the aforementioned processes. Downregulation of miR‑623 in breast cancer is associated with the development of breast cancer and indicates a poor prognosis of patients. The downregulation of miR‑623 promotes cell proliferation, migration and invasion of breast cancer. The findings of the present study indicate that miR‑623 functions as a prognosis biomarker and a tumor suppressor in breast cancer, which provides a potential therapeutic target for patients with breast cancer.

View Figures

View References

1	Espie M: The management of breast cancer. Diagn Interv Imaging. 95:753–757. 2014. View Article : Google Scholar : PubMed/NCBI
2	Shimizu C: Breast cancer in young women: Its biological and clinical uniqueness and needs of comprehensive care. Breast Cancer. 21:641–642. 2014. View Article : Google Scholar : PubMed/NCBI
3	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
4	Li T, Mello-Thoms C and Brennan PC: Descriptive epidemiology of breast cancer in China: Incidence, mortality, survival and prevalence. Breast Cancer Res Treat. 159:395–406. 2016. View Article : Google Scholar : PubMed/NCBI
5	Sorscher S: Prognosis of patients with multifocal breast cancer. Hum Pathol. 84:335–336. 2019. View Article : Google Scholar : PubMed/NCBI
6	Plichta JK: Breast cancer prognostic staging and internal mammary lymph node metastases: A brief overview. Chin Clin Oncol. 8:S112019. View Article : Google Scholar : PubMed/NCBI
7	Van Langenberg A: Prognosis after breast recurrence following conservative surgery and radiotherapy in patients with node-negative breast cancer. Br J Surg. 87:681–683. 2000. View Article : Google Scholar : PubMed/NCBI
8	Hwang J, Min BH, Jang J, Kang SY, Bae H, Jang SS, Kim JI and Kim KM: MicroRNA expression profiles in gastric carcinogenesis. Sci Rep. 8:143932018. View Article : Google Scholar : PubMed/NCBI
9	Lee YS and Dutta A: MicroRNAs in cancer. Annu Rev Pathol. 4:199–227. 2009. View Article : Google Scholar : PubMed/NCBI
10	Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
11	Mohr AM and Mott JL: Overview of microRNA biology. Semin Liver Dis. 35:3–11. 2015. View Article : Google Scholar : PubMed/NCBI
12	Yates LA, Norbury CJ and Gilbert RJ: The long and short of microRNA. Cell. 153:516–519. 2013. View Article : Google Scholar : PubMed/NCBI
13	Iorio MV and Croce CM: MicroRNA dysregulation in cancer: Diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar : PubMed/NCBI
14	Kallioniemi A: Molecular signatures of breast cancer-predicting the future. N Engl J Med. 347:2067–2068. 2002. View Article : Google Scholar : PubMed/NCBI
15	Xu B, Liu J, Xiang X, Liu S, Zhong P, Xie F, Mou T and Lai L: Expression of miRNA-143 in pancreatic cancer and its clinical significance. Cancer Biother Radiopharm. 33:373–379. 2018. View Article : Google Scholar : PubMed/NCBI
16	Zheng L, Jiao W, Song H, Qu H, Li D, Mei H, Chen Y, Yang F, Li H, Huang K and Tong Q: miRNA-558 promotes gastric cancer progression through attenuating Smad4-mediated repression of heparanase expression. Cell Death Dis. 7:e23822016. View Article : Google Scholar : PubMed/NCBI
17	Xiao S, Zhu H, Luo J, Wu Z and Xie M: miR425-5p is associated with poor prognosis in patients with breast cancer and promotes cancer cell progression by targeting PTEN. Oncol Rep. 42:2550–2560. 2019.PubMed/NCBI
18	Li S, Xu JJ and Zhang QY: MicroRNA-132-3p inhibits tumor malignant progression by regulating lysosomal-associated protein transmembrane 4 beta in breast cancer. Cancer Sci. 110:3098–3109. 2019. View Article : Google Scholar : PubMed/NCBI
19	Tang W, Zhang X, Tan W, Gao J, Pan L, Ye X, Chen L and Zheng W: miR-145-5p suppresses breast cancer progression by inhibiting SOX2. J Surg Res. 236:278–287. 2019. View Article : Google Scholar : PubMed/NCBI
20	Jiang L, Yang W, Bian W, Yang H, Wu X, Li Y, Feng W and Liu X: MicroRNA-623 targets cyclin D1 to inhibit cell proliferation and enhance the chemosensitivity of cells to 5-fluorouracil in gastric cancer. Oncol Res. 27:19–27. 2018. View Article : Google Scholar : PubMed/NCBI
21	Wei S, Zhang ZY, Fu SL, Xie JG, Liu XS, Xu YJ, Zhao JP and Xiong WN: Hsa-miR-623 suppresses tumor progression in human lung adenocarcinoma. Cell Death Dis. 7:e23882016. View Article : Google Scholar : PubMed/NCBI
22	Chen Y, Peng S, Cen H, Lin Y, Huang C, Chen Y, Shan H, Su Y and Zeng L: MicroRNA hsa-miR-623 directly suppresses MMP1 and attenuates IL-8-induced metastasis in pancreatic cancer. Int J Oncol. 55:142–156. 2019.PubMed/NCBI
23	Edge SB and Compton CC: The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
26	Li G, Hu J and Hu G: Biomarker studies in early detection and prognosis of breast cancer. Adv Exp Med Biol. 1026:27–39. 2017. View Article : Google Scholar : PubMed/NCBI
27	Li Q, Wang Y, Hu R and Yang G: Dysregulation of SPRR3/miR-876-3p axis contributes to tumorigenesis in non-small-cell lung cancer. Onco Targets Ther. 13:2411–2419. 2020. View Article : Google Scholar : PubMed/NCBI
28	Sahami-Fard MH, Kheirandish S and Sheikhha MH: Expression levels of miR-143-3p and −424-5p in colorectal cancer and their clinical significance. Cancer Biomark. 24:291–297. 2019. View Article : Google Scholar : PubMed/NCBI
29	Zhang Z, Zhang J, Li J, Geng H, Zhou B, Zhang B and Chen H: miR-320/ELF3 axis inhibits the progression of breast cancer via the PI3K/AKT pathway. Oncol Lett. 19:3239–3248. 2020.PubMed/NCBI
30	Feng Y, Yang C, Hu D, Wang X and Liu X: miR-675 promotes disease progression of non-small cell lung cancer via activating NF-κB signaling pathway. Cell Mol Biol (Noisy-le-grand). 63:7–10. 2017. View Article : Google Scholar : PubMed/NCBI
31	Liu W, Xu Y, Guan H and Meng H: Clinical potential of miR-940 as a diagnostic and prognostic biomarker in breast cancer patients. Cancer Biomark. 22:487–493. 2018. View Article : Google Scholar : PubMed/NCBI
32	Qiu C, Huang F, Zhang Q, Chen W and Zhang H: miR-205-3p promotes proliferation and reduces apoptosis of breast cancer MCF-7 cells and is associated with poor prognosis of breast cancer patients. J Clin Lab Anal. 33:e229662019. View Article : Google Scholar : PubMed/NCBI
33	Hamam R, Ali AM, Alsaleh KA, Kassem M, Alfayez M, Aldahmash A and Alajez NM: microRNA expression profiling on individual breast cancer patients identifies novel panel of circulating microRNA for early detection. Sci Rep. 6:259972016. View Article : Google Scholar : PubMed/NCBI
34	Li Q, Liu J, Jia Y, Li T and Zhang M: miR-623 suppresses cell proliferation, migration and invasion through direct inhibition of XRCC5 in breast cancer. Aging (Albany NY). 12:10246–10258. 2020. View Article : Google Scholar : PubMed/NCBI
35	Bi CW, Zhang GY, Bai Y, Zhao B and Yang H: Increased expression of miR-153 predicts poor prognosis for patients with prostate cancer. Medicine (Baltimore). 98:e167052019. View Article : Google Scholar : PubMed/NCBI
36	Zeng B, Li Y, Feng Y, Lu M, Yuan H, Yi Z, Wu Y, Xiang T, Li H and Ren G: Downregulated miR-1247-5p associates with poor prognosis and facilitates tumor cell growth via DVL1/Wnt/β-catenin signaling in breast cancer. Biochem Biophys Res Commun. 505:302–308. 2018. View Article : Google Scholar : PubMed/NCBI
37	Das J, Gayvert KM and Yu H: Predicting cancer prognosis using functional genomics data sets. Cancer Inform. 13 (Suppl 5):S85–S88. 2014.